ArticleCellular & molecular biology letters2025
Ribosomal protein RPL7A modulates lung adenocarcinoma progression via circRANBP17-UPF1-mediated SIRT6 degradation.
Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heat shock protein family D member 1 (HSPD1) modulates ribosome-related pathways and protein synthesis in lung adenocarcinoma.Molecular and cellular biochemistry · 2026Article
- Single-cell transcriptomic analysis reveals that the circRNA circGCLM promotes tumorigenesis and confers cisplatin resistance in NSCLC through the miR-505-3p/ERBB4 axis.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLung cancer, primarily lung adenocarcinoma (LUAD), is the leading cause of cancer-related deaths worldwide. Despite extensive research, the mechanisms behind LUAD progression remain inadequately understood, underscoring the need for new biomarkers and therapeutic targets. Ribosomal proteins, traditionally associated with protein synthesis, are gaining recognition for their roles in tumorigenesis, though many functions remain unexplored.
methodsThis study utilized single-cell transcriptomic data and bioinformatics analyses to identify potential LUAD biomarkers. Selected biomarkers were validated using quantitative PCR (qPCR) and immunofluorescence on clinical samples. Functional roles were assessed through in vivo and in vitro assays, including migration, invasion, and proliferation studies. Mechanistic insights were gained via mRNA stability assays, RNA immunoprecipitation, fluorescence in situ hybridization, and dual luciferase reporter assays.
resultsRPL7A is a significant prognostic marker with elevated expression in metastatic LUAD tissues. Clinical validation shows that high RPL7A expression correlates with LUAD occurrence and poor overall survival (OS) (hazard ratio > 1). RPL7A knockdown inhibits LUAD cell migration, invasion, and proliferation, underscoring its key role in tumor progression. Mechanistically, RPL7A impacts lipid metabolism and the AKT pathway. Crucially, RPL7A regulates circRANBP17, a circRNA linked to LUAD metastasis and lipid metabolism. This interaction forms a complex with UPF1 to destabilize SIRT6 mRNA, a critical factor in lipogenesis. The resulting downregulation of SIRT6 highlights how RPL7A and circRANBP17 contribute to altered lipid metabolism and tumor progression in LUAD.
conclusionsOur findings demonstrate that RPL7A promotes LUAD progression through circRANBP17-UPF1-mediated SIRT6 degradation, positioning RPL7A as a potential therapeutic target in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.